The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Three-year follow-up of ATTRACTION-3: A phase III study of nivolumab (Nivo) in patients with advanced esophageal squamous cell carcinoma (ESCC) that is refractory or intolerant to previous chemotherapy.
 
Keisho Chin
No Relationships to Disclose
 
Ken Kato
Honoraria - Bristol-Myers Squibb; Lilly; Ono Pharmaceutical
Consulting or Advisory Role - BeiGene; MSD; Oncolys BioPharma; Ono Pharmaceutical
Research Funding - Beigene (Inst); MSD Oncology (Inst); Ono Pharmaceutical (Inst); Shionogi (Inst)
 
Byoung Chul Cho
Leadership - Gencurix; Interpark Bio
Stock and Other Ownership Interests - Bridgebio; Cyrus Therapeutics; Gencurix; Interpark Bio; Kanaph Therapeutics; Theravance
Consulting or Advisory Role - AstraZeneca; Blueprint medicines; Boehringer Ingelheim; Bridgebio; Bridgebio; Bristol-Myers Squibb; Cyrus Therapeutics; Guardant Health; Janssen; Kanaph Therapeutics; Lilly; medpacto; MSD; Novartis; Ono Pharmaceutical; Pfizer; Roche; Takeda; Yuhan
Research Funding - Abbvie; AstraZeneca; Bayer; Blueprint medicines; Champions Oncology; Dizal Pharma; Dong-A ST; GI Innovation; Interpark Bio; Janssen; Lilly; medpacto; Mogam Biotechnology Research Institue; MSD; Novartis; Ono Pharmaceutical; Yuhan
Patents, Royalties, Other Intellectual Property - Champions Oncology
Other Relationship - Champions Oncology; DAAN Biotherapeutics
 
Masanobu Takahashi
Speakers' Bureau - Bristol-Myers Squibb Japan; Daiichi Sankyo; Ono Pharmaceutical; Taiho Pharmaceutical
Research Funding - Ono Pharmaceutical
 
Morihito Okada
Speakers' Bureau - Chugai Pharma
Research Funding - Chugai Pharma
 
Chen-Yuan Lin
No Relationships to Disclose
 
Shigenori Kadowaki
Honoraria - Bayer; Bristol-Myers Squibb; Chugai Pharma; Daiichi Sankyo; Eisai; Lilly; Merck KGaA; Ono Pharmaceutical; Yakult Pharmaceutical
Research Funding - Chugai Pharma (Inst); Lilly (Inst); MSD (Inst); Nobelpharma (Inst); Ono Pharmaceutical (Inst); Taiho Pharmaceutical (Inst)
 
Myung-Ju Ahn
Honoraria - AstraZeneca; Lilly; MSD; TAKEDA
Consulting or Advisory Role - Alpha pharmaceutical; AstraZeneca; Boehringer Ingelheim; Lilly; MSD; TAKEDA
 
Yasuo Hamamoto
Consulting or Advisory Role - Chugai Pharma; Dainippon Sumitomo Pharma
Research Funding - Bristol-Myers Squibb Japan; Lilly Japan; MSD Oncology; Ono Pharmaceutical
 
Yuichiro Doki
Honoraria - Chugai Pharma; Daiichi Sankyo; Lilly Japan; MSD; Ono Pharmaceutical; Otsuka; Taiho Pharmaceutical
Consulting or Advisory Role - Ono Pharmaceutical
Research Funding - Chugai Pharma; Ono Pharmaceutical; Taiho Pharmaceutical; Yakult Honsha
 
Chueh-Chuan Yen
Honoraria - Amgen; Eisai; Lilly; Merck Sharp & Dohme
Consulting or Advisory Role - Lilly; Lilly; Merck Sharp & Dohme
Research Funding - Athenex (Inst); Deciphera (Inst); Efficient Pharma Management Corp. (Inst); Eisai (Inst); Lilly (Inst); Ono Pharmaceutical (Inst); Taiwan Liposome (Inst)
Travel, Accommodations, Expenses - Merck Sharp & Dohme; Ono Pharmaceutical; Roche
 
Yutaro Kubota
No Relationships to Disclose
 
Sung-Bae Kim
Honoraria - DAEHWA Pharmaceutical; ISU ABXIS
Consulting or Advisory Role - AstraZeneca; DAEHWA Pharmaceutical; ISU Abxis; Lilly (Inst)
Research Funding - Dongkook Pharma (Inst); Genzyme (Inst); Novartis (Inst)
 
Chih-Hung Hsu
Honoraria - Bristol-Myers Squibb; Merck Sharp & Dohme; Ono Pharmaceutical; Roche
Consulting or Advisory Role - Bristol-Myers Squibb; Lilly; Merck Serono; MSD; Ono Pharmaceutical; Roche/Genentech
Research Funding - AstraZeneca (Inst); BeiGene (Inst); Bristol-Myers Squibb (Inst); Genentech (Inst); Johnson & Johnson (Inst); Merck Serono (Inst); MSD (Inst); Nucana (Inst); Ono Pharmaceutical (Inst); Taiho Pharmaceutical (Inst)
Travel, Accommodations, Expenses - Merck Sharp & Dohme; Ono Pharmaceutical; Roche/Genentech
 
Eva Holtved
No Relationships to Disclose
 
Ioannis Xynos
Employment - Bristol-Myers Squibb
Stock and Other Ownership Interests - Bristol-Myers Squibb
 
Yasuhiro Matsumura
Employment - Ono Pharmaceutical
 
Akira Takazawa
Employment - Ono Pharmaceutical
 
Yuko Kitagawa
Honoraria - Asahi Kasei; Astellas Pharma; Chugai Pharma; Dainippon Sumitomo Pharma; EA Pharma; Eisai; Kaken Pharmaceutical; Nihon Pharma; Ono Pharmaceutical; Otsuka; Otsuka; Sanofi; Shionogi; Taiho Pharmaceutical; Taisho Toyama Pharma; Yakult Honsha
Research Funding - Asahi Kasei (Inst); Astellas Pharma (Inst); Chugai Pharma (Inst); Dainippon Sumitomo Pharma (Inst); EA Pharma (Inst); Eisai (Inst); Kaken Pharmaceutical (Inst); Kyouwa Hakkou Kirin Co., Ltd. (Inst); Medicon (Inst); Nihon Pharma (Inst); Nippon Covidien (Inst); Ono Pharmaceutical (Inst); Otsuka (Inst); Otsuka (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst); Teijin Pharma (Inst); Toyama Chemical Co (Inst); TSUMURA & CO. (Inst); Yakult Honsha (Inst)